New mRNA vaccine takes on tough cancers
Disease control
Recruiting now
This early-stage trial tests a new mRNA vaccine called ABO2102, designed to target cancers with specific KRAS mutations. About 101 adults with advanced solid tumors will receive the vaccine alone or with another drug (Sintilimab). The study focuses on safety and how the body resp…
Phase: PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC